Hub biomarkers for the diagnosis and treatment of glioblastoma based on microarray technology

• Main Authors: Kai Cui, Jin-hui Chen, Yang-fan Zou, Shu-yuan Zhang, Bing Wu, Kai Jing, Li-weng Li, Liang Xia, Caixing Sun, Ya-lan Dong
• Format: Article
• Language: English
• Published: SAGE Publishing 2021-05-01
• Series: Technology in Cancer Research & Treatment
• Online Access: https://doi.org/10.1177/1533033821990368

Background: Glioblastoma (GBM) is the most common clinical intracranial malignancy worldwide, and the most common supratentorial tumor in adults. GBM mainly causes damage to the brain tissue, which can be fatal. This research explored potential gene targets for the diagnosis and treatment of GBM using bioinformatic technology. Methods: Public data from patients with GBM and controls were downloaded from the Gene Expression Omnibus database, and differentially expressed genes (DEGs) were identified by Gene Expression Profiling Interactive Analysis (GEPIA) and Gene Expression Omnibus 2R (GEO2R). Construction of the protein–protein interaction network and the identification of a significant module were performed. Subsequently, hub genes were identified, and their expression was examined and compared by real-time quantitative (RT-q)PCR between patients with GBM and controls. Results: GSE122498 (GPL570 platform), GSE104291 (GPL570 platform), GSE78703_DMSO (GPL15207 platform), and GSE78703_LXR (GPL15207 platform) datasets were obtained from the GEO. A total of 130 DEGs and 10 hub genes were identified by GEPIA and GEO2R between patients with GBM and controls. Of these, strong connections were identified in correlation analysis between CCNB1 , CDC6 , KIF23 , and KIF20A . RT-qPCR showed that all 4 of these genes were expressed at significantly higher levels in patients with GBM compared with controls. Conclusions: The hub genes CCNB1 , CDC6 , KIF23 , and KIF20A are potential biomarkers for the diagnosis and treatment of GBM.